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j ourna l homepage: www.eb iomed ic ine.comEditorialBrexit and Translational ResearchIn a historic referendum on June 23, 2016, the UK voted to leave the
European Union (EU) after more than four decades of membership. For
the time being, the UK is still a member of the EU until the UK govern-
ment triggers Article 50 of the Lisbon Treaty–which probably won't
happen before the end of 2016. A minimum of 2 years of negotiations
will follow before theUK ceases to be an EUmember. This unprecedent-
ed Brexit decision has created a shockwave resonating not only within
the UK and Europe, but also across the globe, affecting amultitude of as-
pects fromﬁnance andpolitics to science.Much of the concernhas come
from the lack of a clear Brexit roadmap and thewidespread uncertainty
as to what the negotiations will include.
So what are the implications of Brexit in translational research?
Given the complexity and multidisciplinary nature of biomedical
science, translational research relies profoundly on collaboration
among scientists and institutes in order to amalgamate expertise and
resources. Internationally coauthored research publication has
increased from around 10% in the 1980s to 40-50% in the 2010s, and
this global trend is the main driving force in research growth. In the
UK, 80% of international collaborators are from the EU, and 15% of aca-
demic staff is non-UK EU nationals. Because one of the core arguments
for Brexit is to limit immigration, this will likely create an unintended
barrier for research collaboration. In fact, there are already some reports
of EU scientists being reluctant to collaborate with UK researchers in EU
funding applications, because EU funding bodies are yet to decide
whether UK scientists will be eligible for funding.
This post-Brexit funding concern could have serious repercussions
for translational research. UK researchers receive nearly £1 billion a
year from EU funding programs such as Horizon 2020; whether or not
they can continue to participate in such funding programs after Brexit
will need to be renegotiated. It's likely that British scientists will have
to compete harder in applying for EU funding–if they are allowed to
apply. Non-EU associated members like Switzerland can participate in
EU funding programs, but they need to pay an associated membership
fee and have to agree to free movement of EU citizens. In 2014, the
Swiss voted to restrict mass immigration, and Switzerland was
suspended from Horizon 2020 as a result. The current uncertainty that
Brexit has created also reduces investors' conﬁdence–safer investment
would be in big pharmas, whereas small to medium biotechnology
companies where much of higher-risk translational research is carried
out would be hit harder in this ﬁnancial climate.
But is it all doom and gloom ﬁnancially? EU funding–although an
important source–only accounts for about 10% of UK research expendi-
ture, while the majority of biomedical research funding comes from the
UK government through Research Councils UK (RCUK) such as Medical
Research Council (MRC) and Biotechnology and Biological Sciences
Research Council (BBSRC), and National Institute of Health Researchhttp://dx.doi.org/10.1016/j.ebiom.2016.08.007
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and the Wellcome Trust. Whether the UK government is prepared to
subsidize the loss in EU funding remains a question. As long as the UK
retains its competitive edge as one of the world's ﬁnancial capitals,
investments should keep streaming in. Last week on July 27,
GlaxoSmithKline afﬁrmed that despite Brexit, the UK remains an attrac-
tive place to invest £275 million across three of its British factories. The
UK has the funding infrastructure to support the whole spectrum of
translational research, with the RCUK funding for basic research, Inno-
vate UK for early prototype stages of development, and private sectors
(e.g., big pharmas) for late-stage development and commercialization
of products.
The EU has been both criticized and praised when it comes to
regulations. It has created thousands of EU regulations to achieve
consistency across the region, from everyday products to sophisticated
aspects of science, technology and medicine. High-level bureaucracy
raises the market-entry bar for small startups with innovative yet un-
tested ideas, thus unintentionally hampering competition. The 2001
European Clinical Trials Directive was created to harmonize regulations
but in fact resulted in higher costs and bureaucracy, and inadvertently
hindered many UK clinical trials. The new EU Clinical Trials Regulation
was then developed with aim to promote clinical trial activity while
keeping the guiding principle of the original Directive–to protect partic-
ipants' safety and rights. After Brexit, the European Medicines Agency
(EMA) will most likely move its London ofﬁce to an EU country.
Which organizations will then regulate health research and medical
product approval in the UK? At the other end of the translational
research spectrum, will there be any regulatory changes in the use of
animals and human tissues for research? Will all of these changes
increase or decrease the level of bureaucracy and will biomedical
research be harder or easier to be conducted? There is much unknown
until more details of the UK-EU negotiation emerge, but perhaps it
would be most prudent to keep all regulations unchanged during this
transition period.
Although Article 50 has not been triggered, there seems to be no
going back on the UK decision to leave the EU. The UK government
now has an arduous task to negotiate the best exit deal for the UK.
Both theUK and EU have assigned teamswhowill lead the negotiations.
On July 19, a joint letter from seven national academies, including the
Royal Society and the Academy of Medical Sciences, was sent to the
UK government, calling it to prioritize scientiﬁc research during
negotiations with the EU, protect research funding and draw up an
agreement in which the UK can actively participate and inﬂuence EU
research policy.
Regardless of what happens, translational research in the UK will
likely endure and thrive, and scientists and health researchers must-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In February 2015, the UK passed a law allowing embryonic mitochon-
drial editing (dubbed by the media as “three-person babies”), thus
giving couples who carry dreadful mitochondrial mutations the chance
to have a healthy baby. This is just one example of the cutting-edge
science that British researchers are doing that no other European
counterparts are legally able to. Innovation and competitiveness is the
prowess of British science that will attract international researchers aswell as funding. If this strength is recognized and built upon after Brexit,
strong research ties between the UK and Europe are expected to be
maintained, which would beneﬁt both sides–while at the same time,
global collaborations between the UK and other leading countries in
biomedical research like the US and China must be further reinforced.
